Trump takes credit for drug price decline, but the reason is complex

Key Points:

• New federal data shows U.S. prescription drug prices fell 0.8% in July and are down 3.1% from a year ago, the steepest annual drop since 1963, with President Trump attributing the decline to his "most favored nation" drug deals and the TrumpRx website.
• Experts suggest the price drop is influenced more by factors such as the Biden-era Inflation Reduction Act allowing Medicare to negotiate drug prices, increased competition from generics and biosimilars, and other market dynamics rather than solely Trump’s policies.
• The impact of Trump’s "most favored nation" deals remains unclear since contracts have not been disclosed and the policies have not fully taken effect, while the TrumpRx website’s claimed savings of $700 million have been questioned for lack of verifiable data.
• Despite the reported price declines, many consumers may not see reduced out-of-pocket costs because the drug price index measures what pharmacies receive, not what patients pay, and overall healthcare costs and insurance premiums continue to rise.
• Experts emphasize that prescription drug price indices do not fully capture consumers’ healthcare spending experiences, which can be affected by insurance coverage, plan differences, and reliance on expensive drugs without cheaper alternatives.